CAR-T therapy modifies a patient’s own T cells so they can better identify and attack cancer cells. But more details are needed on the intricate mechanisms behind the cells’ cancer-killing effects.

The Broad Institute of MIT and Harvard has launched a new, major initiative to support machine-learning-powered research into the life sciences.

The FDA approved a new type of medical device to help improve the walking gait of people with multiple sclerosis in combination with a therapeutic program for exercise and balance.

BrainScope launched a new, FDA-cleared algorithm for its point-of-care, brain-scanning headset that checks for traumatic injuries, hidden bleeds and concussions.

Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics.

Alkermes’ virtual R&D day went down well with analysts, as it showed off a few early-stage incremental updates and reiterated its attempts for seeking out some new ops and collabs.

After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the agency called a panel of outside experts to chew over the drug’s application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.

Many of the beneficial bacteria that reside in the human gut microbiome are being studied for their potential in treating a range of diseases, from asthma to Parkinson’s. But the founders of an Israeli startup believe there’s also inspiration for novel treatments to be found in the microbiomes of more than 200 wild animals.

Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.

BrainStorm Cell Therapeutics has presented phase 2 data on its stem cell therapy in patients with multiple sclerosis (MS). The small, open-label clinical trial linked autologous therapy NurOwn to a 25% improvement in measures of mobility and dexterity in around 14% of patients.